The Intersectoral Coordination Unit for the Sustainable Intensification of Peritoneal Dialysis in Schleswig-Holstein (SKIP-SH) cohort study

• Published in: BMC nephrology 2024-03, Vol.25 (1), p.75-75, Article 75
• Main Authors: Wülfrath, Hauke S, Schrumpf, Thorben, von Samson-Himmelstjerna, Friedrich A, Voran, Jakob, Zhang, Yao, Esser, Grit, Thomsen, Sarah-Yasmin, Messtorff, Maja L, Riebeling, Theresa, Kakavand, Nassim, Schmitt, Roland, Schulte, Kevin, Kolbrink, Benedikt
• Format: Article
• Language: English
• Subjects: Biobanking; Biomaterials; Biomedical materials; Care and treatment; Caregivers; Chronic kidney failure; Cohort analysis; Consent; Continuous ambulatory peritoneal dialysis; Datasets; Design; Effluents; End-stage renal disease; Health care; Hemodialysis; Kidney diseases; Kidney replacement therapy; Kidneys; Life expectancy; Methods; Patients; Peritoneal dialysis; Peritoneum; Prospective cohort study; Quality of life; Research programs; Translation
• ISSN: 1471-2369; 1471-2369
• DOI: 10.1186/s12882-024-03519-9

Peritoneal dialysis (PD) remains underutilised in Germany, prompting the initiation of the Sustainable Intensification of Peritoneal Dialysis in Schleswig-Holstein (SKIP-SH) project. The SKIP-SH cohort study aims to demonstrate the presumed benefits of PD, including enhanced quality of life and reduced healthcare personnel requirements, and to generate data to strengthen the use of PD. The prospective SKIP-SH cohort study recruits patients with advanced chronic kidney disease (CKD) and their caregivers. Comprehensive data, including demographic information, medical history, clinical course, laboratory data, and quality-of-life assessments, are collected. Additionally, biomaterials will be obtained. Primary study objectives are documenting the clinical course and complications, time on therapy for new dialysis patients, reasons influencing treatment modality choices, circumstances at the initiation of dialysis, and quality of life for patients with CKD and their caregivers. The collected biomaterials will serve as a basis for further translational research. Secondary objectives include identifying factors impacting disease-related quality of life, clinical complications, and therapy dropout, estimating ecological footprints, and evaluating healthcare costs and labour time for initiating and sustaining PD treatment. PD is notably underutilised in Germany. The current therapy approach for advanced CKD often lacks emphasis on patient-focused care and quality-of-life considerations. Furthermore, adequate explorative research programs to improve our knowledge of mechanisms leading to disease progression and therapy failure in PD patients are scarce. The overarching goal of the SKIP-SH cohort study is to address the notably low PD prevalence in Germany whilst advocating for a shift towards patient-focused care, quality-of-life considerations, and robust translational research. This study was registered with the German trial registry (Deutsches Register klinischer Studien) on November 7, 2023, under trial number DRKS00032983.